Comparative Pharmacology
Head-to-head clinical analysis: IDAMYCIN versus VALSTAR PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IDAMYCIN versus VALSTAR PRESERVATIVE FREE.
IDAMYCIN vs VALSTAR PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Idarubicin is an anthracycline antineoplastic agent that intercalates with DNA and inhibits topoisomerase II, leading to inhibition of DNA replication and transcription, and ultimately cell death. It also generates free radicals and induces apoptosis.
Valrubicin is a semisynthetic anthracycline derivative that intercalates into DNA, inhibiting nucleic acid synthesis and inducing cell death. It is cytotoxic to both dividing and non-dividing cells.
12 mg/m² IV daily for 3 days (acute myeloid leukemia) or 12 mg/m² IV daily for 3 days (acute lymphoblastic leukemia); maximum cumulative dose 600 mg/m².
Intravesical instillation of 800 mg (40 mL of 20 mg/mL solution) weekly for 6 weeks, retained in bladder for 2 hours.
None Documented
None Documented
Terminal elimination half-life: 20-30 hours (mean ~22 hours). Prolonged in severe hepatic impairment (up to 40 hours) and may be extended in patients with renal impairment due to accumulation of active metabolite idarubicinol (half-life > 60 hours).
Terminal elimination half-life: 3-5 hours; clinical context: supports intravesical instillation with minimal systemic absorption.
Primarily hepatic metabolism; biliary excretion of metabolites accounts for ~50% of total elimination. Renal excretion of unchanged drug is minimal (<10%). Approximately 30-40% of the dose is recovered in urine as metabolites. Fecal elimination of metabolites accounts for ~50%.
Renal: approximately 50-70% excreted unchanged in urine within 72 hours; biliary/fecal: minor (<5%).
Category C
Category C
Anthracycline Antineoplastic
Anthracycline Antineoplastic